MEI Pharma (MEIP)

• Market cap: $15.4M
• 1 day: 0.43%
• 5 days: -5.71%
• 1 month: -14.13%
• 3 months: -10.47%
• 6 months: -24.26%
• Year to date: -9.41%
• 1 year: -41.07%
• 5 years: -87.17%
• 10 years: -93.44%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Employees: 28

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

7% more funds holding

Funds holding: 30 [Q3] → 32 (+2) [Q4]

0.55% less ownership

Funds ownership: 41.16% [Q3] → 40.61% (-0.55%) [Q4]

15% less capital invested

Capital invested by funds: $7.81M [Q3] → $6.65M (-$1.16M) [Q4]

50% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 8

97% less call options, than puts

Call options by funds: $1K | Put options by funds: $31K